Corcept Therapeutics is surging 22.7% today following the announcement that the company has received FDA approval for a new cancer therapy. This positive regulatory development serves as the primary catalyst for the move, effectively overshadowing recent negative sentiment surrounding ongoing securities class action lawsuits related to previous FDA issues. The stock is outperforming the broader biotechnology sector, which is seeing mixed results today, as investors react to the significant de-risking event provided by the new drug approval.
Click any event to see why CORT moved that day
No significant catalyst events detected.